Mercado Ásia-Pacífico de Drogas Injetáveis ​​Liofilizadas – Tendências da Indústria e Previsão para 2028

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado Ásia-Pacífico de Drogas Injetáveis ​​Liofilizadas – Tendências da Indústria e Previsão para 2028

  • Pharmaceutical
  • Publish Reports
  • Jun 2021
  • Asia-Pacific
  • 350 Páginas
  • Número de tabelas: 283
  • Número de figuras: 49

>Mercado de medicamentos injetáveis ​​​​liofilizados da Ásia-Pacífico, por embalagem (frascos, seringas de câmara dupla, cartuchos de câmara dupla e outros), classe de medicamentos (antiinfecciosos, antineoplásicos, diuréticos, inibidor da bomba de protões, anestésico, anticoagulante, AINEs, corticosteróides e outros) ), Forma (Pó e Líquido), Indicação (Oncologia, Doenças Autoimunes, Distúrbios Hormonais, Doenças Respiratórias, Distúrbios Gastrointestinais, Distúrbios Dermatológicos, Doenças Oftalmológicas e Outras), Via de Administração (Intravenosa/Infusão, Intramuscular e Outras), Utilizador Final ( Hospital, Clínicas, Cuidados de Saúde Domiciliários e Outros), Canal de Distribuição (Concurso Directo, Vendas a Retalho e Outros), País (Japão, China, Austrália, Índia, Coreia do Sul, Singapura, Indonésia, Tailândia, Malásia, Filipinas, Vietname, Resto da Ásia -Pacífico) Tendências e previsões da indústria para 2028.

Mercado de medicamentos injetáveis ​​​​liofilizados da Ásia-Pacífico

Análise de mercado e insights : Mercado de medicamentos injetáveis ​​​​liofilizados da Ásia-Pacífico

Espera-se que o mercado de drogas injetáveis ​​​​liofilizadas ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 7,7%, devendo atingir os US$ 1.351,81 Milhões no período de previsão de 2021 a 2028. Um grande número de players do mercado estão envolvidos na oferta de produtos de medicamentos injetáveis ​​​​liofilizados com inovações que abrem caminho para o crescimento do mercado de medicamentos injetáveis ​​​​liofilizados.

A liofilização é um método de liofilização para remover água de um produto acabado. Os produtos de saída da liofilização são congelados sob alto vácuo. Nas indústrias biotecnológica e farmacêutica, o processo de liofilização é utilizado para criar produtos de alta qualidade com um prazo de validade mais longo.

O aumento das condições de saúde crónicas, o aumento da população geriátrica e geral com defeitos cardíacos e neurológicos, a expansão do pipeline de medicamentos injetáveis ​​​​liofilizados, a redução do risco de administração de medicamentos injetáveis ​​​​liofilizados com seringas diluentes pré-cheias e o avanço tecnológico devido ao aumento da investigação e desenvolvimento estão a impulsionar a Ásia-Pacífico mercado de medicamentos injetáveis ​​​​liofilizados.

Além disso, a liofilização permite o transporte e armazenamento seguros destas substâncias até que sejam necessárias. Os medicamentos injetáveis ​​devem agora ser liofilizados devido ao aumento das questões de segurança. Após um longo período de armazenamento, os medicamentos injetáveis ​​​​​​liofilizados revelaram-se mais seguros e mais convenientes de administrar do que outros artigos secos.

O relatório de mercado de medicamentos injetáveis ​​​​liofilizados fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado , aprovações de produtos, decisões estratégicas, lançamentos de produtos. Para compreender a análise e o cenário do mercado contacte-nos para um Analyst Brief, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.

Mercado de medicamentos injetáveis ​​​​liofilizados da Ásia-Pacífico

Âmbito e dimensão do mercado de medicamentos injetáveis ​​​​liofilizados da Ásia-Pacífico

O mercado dos medicamentos injetáveis ​​​​liofilizados está categorizado em sete segmentos notáveis ​​que se baseiam na embalagem, classe do medicamento, forma, indicação, via de administração, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.

  • Com base nas embalagens, o mercado dos medicamentos injetáveis ​​​​​liofilizados está segmentado em frascos, seringas de dupla câmara, cartuchos de dupla câmara e outros. Em 2021, espera-se que o segmento dos frascos domine o mercado dos medicamentos injetáveis ​​​​liofilizados porque a maioria dos medicamentos injetáveis ​​​​​liofilizados são embalados em frascos, pelo que é influente e também está a crescer no mercado.
  • Com base na classe de medicamentos, o mercado dos medicamentos injetáveis ​​​​liofilizados está segmentado em anti-infecciosos, antineoplásicos, diuréticos , inibidores da bomba de protões, anestésicos, anticoagulantes, AINEs, corticosteróides e outros. Em 2021, prevê-se que o segmento anti-infeccioso domine o mercado dos medicamentos injetáveis ​​​​liofilizados devido à elevada prevalência de doenças crónicas na região asiática que está a fomentar a necessidade de antibióticos e medicamentos antivirais.
  • Com base na forma, o mercado dos medicamentos injetáveis ​​​​​​liofilizados está segmentado em e líquido. Em 2021, espera-se que o segmento do pó domine o mercado dos medicamentos injetáveis ​​​​liofilizados porque é altamente utilizado no armazenamento e transporte na região Ásia-Pacífico.
  • Com base na indicação, o mercado dos medicamentos injetáveis ​​​​liofilizados está segmentado em oncologia , doenças autoimunes, distúrbios hormonais, doenças respiratórias, distúrbios gastrointestinais, distúrbios dermatológicos, doenças oftalmológicas e outros. Em 2021, prevê-se que o segmento da oncologia domine o mercado dos medicamentos injetáveis ​​​​liofilizados, uma vez que os medicamentos injetáveis ​​​​liofilizados são utilizados ​​em elevada utilização em oncologia na região asiática.
  • Com base na via de administração, o mercado dos medicamentos injetáveis ​​​​​liofilizados está segmentado em intravenoso/infusão, intramuscular e outros. Em 2021, prevê-se que o segmento intravenoso/infusão domine o mercado dos medicamentos injetáveis ​​​​liofilizados devido à biodisponibilidade de 100% do medicamento por esta via de administração.
  • On the basis of end user, the lyophilized injectable drugs market is segmented into hospital, clinics, home healthcare and others. In 2021, hospital segment is expected to dominate the lyophilized injectable drugs market because of the presence of skilled professionals in the Asian region.
  • On the basis of distribution channel, the lyophilized injectable drugs market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is expected to dominate the lyophilized injectable drugs market because the demand for direct tender is high in the Asia-Pacific region.

Lyophilized Injectable Drugs Market Country Level Analysis

The lyophilized injectable drugs market is analysed and market size information is provided by the country, packaging, drug class, form, indication, route of administration, end user and distribution channel as referenced above.

The countries covered in the Asia-Pacific lyophilized injectable drugs market Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, and Rest of Asia-Pacific.

China is expected to dominate the market due to rise in chronic health conditions and increase in geriatric population with chronic diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

New Product Launches by Manufactures is Creating New Opportunities for Players in the Lyophilized Injectable Drugs Market

Lyophilized Injectable Drugs Market also provides you with detailed market analysis for every country growth in aesthetic industry with Lyophilized Injectable Drugs Market sales, impact of advancement in the lyophilized injectable drugs market and changes in regulatory scenarios with their support for the lyophilized injectable drugs market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Lyophilized Injectable Drugs Market Share Analysis

O panorama competitivo do mercado de medicamentos injetáveis ​​​​​liofilizados fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura e amplitude do produto, domínio de aplicação, curva de segurança da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco da empresa relacionado com o mercado de medicamentos injetáveis ​​​​liofilizados.

As principais empresas que fornecem medicamentos injetáveis ​​​​liofilizados no mercado de medicamentos injetáveis ​​​​liofilizados da Ásia-Pacífico são a Affy Pharma Pvt Ltd., a Genex Pharma, a AuroMedics Pharma LLC Pharma LLC (uma subsidiária da Aurobindo Pharma), a Astellas Pharma US, Inc . Pharma Inc.), Aristopharma Ltd., Pfizer Inc., Sanofi, Celon Laboratories Unip. Lda. e Baxter, entre outros. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

Muitos contratos e acordos são também iniciados por empresas em todo o mundo que também estão a acelerar o mercado dos medicamentos injetáveis ​​​​​​liofilizados.

  • Em novembro de 2019, a Pfizer, Inc. anunciou que a sua divisão, denominada Upjohn, foi combinada com a Mylan NV e formou uma nova empresa chamada Viatris Inc. o seu produto no mercado.

A colaboração, as joint ventures e outras estratégias dos players do mercado estão a potenciar o mercado da empresa no mercado das drogas injetáveis ​​​​liofilizadas, o que também oferece o benefício para a organização melhorar a sua oferta para o mercado das drogas injetáveis ​​​​liofilizadas.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PACKAGING LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: REGULATORY FRAMEWORK

5 EPIDEMIOLOGY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN CHRONIC HEALTH CONDITIONS

6.1.2 SAFE TRANSIT AND STORAGE OF THESE SUBSTANCES UNTIL THEIR END-USE

6.1.3 INCREASE IN GERIATRIC POPULATION WITH CHRONIC DISEASES

6.1.4 EXPANSION OF PIPELINE OF LYOPHILIZED INJECTABLE DRUGS

6.1.5 TECHNOLOGICAL ADVANCEMENTS

6.2 RESTRAINTS

6.2.1 RISK OF NEEDLESTICK INJURIES

6.2.2 INCREASE IN NUMBER OF PRODUCT RECALLS FOR LYOPHILIZED DRUGS AND PACKAGING TYPE

6.3 OPPORTUNITIES

6.3.1 RISE IN REGULATORY APPROVALS FOR LYOPHILIZED DRUGS

6.3.2 STRATEGIC INITIATIVES OF KEY MARKET PLAYERS

6.3.3 QUALITY CONCERNS

6.4 CHALLENGES

6.4.1 CHALLENGES ASSOCIATED WITH MANUFACTURING LYOPHILIZED VIALS FOR PARENTERAL PRODUCTS

6.4.2 TIME-CONSUMING PROCESS AND HIGH COST

7 IMPACT OF COVID-19 ON THE ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT IN DEMAND

7.3 IMPACT ON SUPPLY

7.4 STRATEGIC INITIATIVE

7.5 CONCLUSION

8 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING

8.1 OVERVIEW

8.2 VIALS

8.3 DUAL-CHAMBER SYRINGES

8.4 DUAL-CHAMBER CARTRIDGES

8.5 OTHERS

9 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS

9.1 OVERVIEW

9.2 ANTI-INFECTIVE’S

9.2.1 ANTIBIOTICS

9.2.1.1 Azithromycin

9.2.1.2 Doxycycline

9.2.1.3 Vancomycin

9.2.1.4 Polymyxin B

9.2.1.5 Piperacillin

9.2.1.6 Tazobactam

9.2.1.7 Others

9.2.2 ANTIFUNGAL

9.2.2.1 Mycamine

9.2.2.2 Caspofungin Acetate

9.2.2.3 Isavuconazonium Sulfate

9.2.2.4 Amphotericin

9.2.2.5 Others

9.2.3 ANTIVIRAL

9.2.3.1 Acyclovir

9.2.3.2 Ganciclovir

9.2.3.3 Remdesivir

9.2.3.4 Others

9.2.4 OTHERS

9.3 ANTINEOPLASTIC

9.3.1 METHOTREXATE

9.3.2 GEMCITABINE

9.3.3 CYTARABINE

9.3.4 FLUDARABINE

9.3.5 DOXORUBICIN

9.3.6 OXALIPLATIN

9.3.7 ZOLEDRONIC ACID

9.3.8 OTHERS

9.4 DIURETICS

9.4.1 CHLOROTHIAZIDE

9.4.2 ETHACRYNIC ACID

9.4.3 ACETAZOLAMIDE

9.4.4 OTHERS

9.5 PROTON PUMP INHIBITOR

9.5.1 ESOMEPRAZOLE SODIUM

9.5.2 PANTOPRAZOLE SODIUM

9.5.3 OMEPRAZOLE

9.5.4 OTHERS

9.6 ANESTHETIC

9.6.1 VECURONIUM BROMIDE

9.6.2 SODIUM THIOPENTAL

9.6.3 LIDOCAINE

9.6.4 OTHERS

9.7 ANTICOAGULANT

9.7.1 COUMADIN

9.7.2 UROKINASE

9.7.3 ANTITHROMBIN (RECOMBINANT)

9.7.4 APIXABAN

9.7.5 RIVAROXABAN

9.7.6 OTHERS

9.8 NSAID’S

9.8.1 INDOMETHACIN

9.8.2 IBUPROFEN

9.8.3 DICLOFENAC

9.8.4 KETOROLAC

9.8.5 OTHERS

9.9 CORTICOSTEROIDS

9.9.1 HYDROCORTISONE

9.9.2 METHYLPREDNISOLONE

9.9.3 OTHERS

9.1 OTHERS

10 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM

10.1 OVERVIEW

10.2 POWDER

10.3 LIQUID

11 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION

11.1 OVERVIEW

11.2 ONCOLOGY

11.3 AUTOIMMUNE DISEASES

11.4 HORMONAL DISORDERS

11.5 RESPIRATORY DISEASES

11.6 GASTROINTESTINAL DISORDERS

11.7 DERMATOLOGICAL DISORDERS

11.8 OPHTHALMIC DISEASES

11.9 OTHERS

12 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 INTRAVENOUS/INFUSION

12.3 INTRAMUSCULAR

12.4 OTHERS

13 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 HOME HEALTHCARE

13.5 OTHERS

14 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDERS

14.3 RETAIL SALES

14.4 OTHERS

15 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION

15.1 ASIA-PACIFIC

15.1.1 JAPAN

15.1.2 CHINA

15.1.3 SOUTH KOREA

15.1.4 INDIA

15.1.5 AUSTRALIA

15.1.6 SINGAPORE

15.1.7 THAILAND

15.1.8 MALAYSIA

15.1.9 INDONESIA

15.1.10 PHILIPPINES

15.1.11 VIETNAM

15.1.12 REST OF ASIA-PACIFIC

16 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 PFIZER INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS KABI AG)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 CIPLA INC.

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 NOVARTIS AG

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 BAXTER

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENTS

18.7 ZYDUS CADILA

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 AFFY PHARMA PVT LTD.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 AMNEAL PHARMACEUTICALS LLC

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENTS

18.1 ARISTOPHARMA LTD.

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 ASTELLAS PHARMA US, INC. (A SUBSIDIARY OF ASTELLAS PHARMA INC.)

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 AUROMEDICS PHARMA LLC (A SUBSIDIARY OF AUROBINDO PHARMA)

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 CELON LABORATORIES PVT.LTD.

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENT

18.14 CIRONDRUGS

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 GENEX PHARMA

18.15.1 COMPANY SNAPSHOT

18.15.2 PRODUCT PORTFOLIO

18.15.3 RECENT DEVELOPMENT

18.16 GILEAD SCIENCES, INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 REVENUE ANALYSIS

18.16.3 PRODUCT PORTFOLIO

18.16.4 RECENT DEVELOPMENTS

18.17 JUBILANT GENERICS LIMITED – A JUBILANT PHARMA COMPANY

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENTS

18.18 OTSUKA AMERICA PHARMACEUTICAL, INC

18.18.1 COMPANY SNAPSHOT

18.18.2 PRODUCT PORTFOLIO

18.18.3 RECENT DEVELOPMENTS

18.19 SANOFI

18.19.1 COMPANY SNAPSHOT

18.19.2 REVENUE ANALYSIS

18.19.3 PRODUCT PORTFOLIO

18.19.4 RECENT DEVELOPMENT

18.2 VIATRIS INC.

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

Lista de Tabela

TABLE 1 PIPELINE LYOPHILIZED INJECTABLE DRUGS

TABLE 2 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 3 ASIA-PACIFIC VIALS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 ASIA-PACIFIC DUAL-CHAMBER SYRINGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 ASIA-PACIFIC DUAL-CHAMBER CARTRIDGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 9 ASIA-PACIFIC ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC PROTON PUMP INHIBITORS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC ANESTHETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 28 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC POWDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC LIQUID IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 33 ASIA-PACIFIC ONCOLOGY IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC AUTOIMMUNE DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC HORMONAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 ASIA-PACIFIC RESPIRATORY DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC GASTROINTESTINAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC DERMATOLOGICAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC OPHTHALMIC DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC INTRAVENOUS/INFUSION IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 ASIA-PACIFIC INTRAMUSCULAR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 ASIA-PACIFIC HOSPITAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 ASIA-PACIFIC CLINICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 ASIA-PACIFIC HOME HEALTHCARE IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 50 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 51 ASIA-PACIFIC DIRECT TENDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 52 ASIA-PACIFIC RETAIL SALES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 53 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 54 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 55 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 56 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 57 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 58 ASIA-PACIFIC ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 59 ASIA-PACIFIC ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 60 ASIA-PACIFIC ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 61 ASIA-PACIFIC ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 62 ASIA-PACIFIC ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 63 ASIA-PACIFIC DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 64 ASIA-PACIFIC PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 65 ASIA-PACIFIC ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 66 ASIA-PACIFIC ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 67 ASIA-PACIFIC NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 68 ASIA-PACIFIC CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 69 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 70 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 71 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 75 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 76 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 77 JAPAN ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 78 JAPAN ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 79 JAPAN ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 80 JAPAN ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 81 JAPAN ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 82 JAPAN DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 83 JAPAN PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 84 JAPAN ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 85 JAPAN ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 86 JAPAN NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 87 JAPAN CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 88 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 89 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 90 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 91 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 93 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 94 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 95 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 96 CHINA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 97 CHINA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 98 CHINA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 99 CHINA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 100 CHINA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 101 CHINA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 102 CHINA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 103 CHINA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 104 CHINA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 105 CHINA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 106 CHINA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 107 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 108 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 109 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 110 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 111 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 112 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 113 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 114 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 115 SOUTH KOREA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 116 SOUTH KOREA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 117 SOUTH KOREA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 118 SOUTH KOREA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 119 SOUTH KOREA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 120 SOUTH KOREA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 121 SOUTH KOREA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 122 SOUTH KOREA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 123 SOUTH KOREA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 124 SOUTH KOREA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 125 SOUTH KOREA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 126 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 127 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 128 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 129 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 130 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 131 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 132 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 133 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 134 INDIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 135 INDIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 136 INDIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 137 INDIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 138 INDIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 139 INDIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 140 INDIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 141 INDIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 142 INDIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 143 INDIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 144 INDIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 145 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 146 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 147 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 148 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 149 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 150 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 151 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 152 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 153 AUSTRALIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 154 AUSTRALIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 155 AUSTRALIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 156 AUSTRALIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 157 AUSTRALIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 158 AUSTRALIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 159 AUSTRALIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 160 AUSTRALIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 161 AUSTRALIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 162 AUSTRALIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 163 AUSTRALIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 164 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 165 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 166 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 167 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 168 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 169 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 170 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 171 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 172 SINGAPORE ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 173 SINGAPORE ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 174 SINGAPORE ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 175 SINGAPORE ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 176 SINGAPORE ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 177 SINGAPORE DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 178 SINGAPORE PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 179 SINGAPORE ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 180 SINGAPORE ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 181 SINGAPORE NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 182 SINGAPORE CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 183 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 184 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 185 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 186 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 187 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 188 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 189 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 190 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 191 THAILAND ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 192 THAILAND ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 193 THAILAND ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 194 THAILAND ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 195 THAILAND ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 196 THAILAND DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 197 THAILAND PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 198 THAILAND ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 199 THAILAND ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 200 THAILAND NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 201 THAILAND CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 202 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 203 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 204 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 205 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 206 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 207 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 208 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 209 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 210 MALAYSIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 211 MALAYSIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 212 MALAYSIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 213 MALAYSIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 214 MALAYSIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 215 MALAYSIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 216 MALAYSIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 217 MALAYSIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 218 MALAYSIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 219 MALAYSIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 220 MALAYSIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 221 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 222 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 223 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 224 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 225 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 226 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 227 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 228 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 229 INDONESIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 230 INDONESIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 231 INDONESIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 232 INDONESIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 233 INDONESIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 234 INDONESIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 235 INDONESIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 236 INDONESIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 237 INDONESIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 238 INDONESIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 239 INDONESIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 240 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 241 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 242 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 243 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 244 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 245 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 246 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 247 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 248 PHILIPPINES ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 249 PHILIPPINES ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 250 PHILIPPINES ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 251 PHILIPPINES ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 252 PHILIPPINES ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 253 PHILIPPINES DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 254 PHILIPPINES PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 255 PHILIPPINES ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 256 PHILIPPINES ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 257 PHILIPPINES NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 258 PHILIPPINES CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 259 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 260 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 261 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 262 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 263 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 264 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 265 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 266 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 267 VIETNAM ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 268 VIETNAM ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 269 VIETNAM ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 270 VIETNAM ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 271 VIETNAM ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 272 VIETNAM DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 273 VIETNAM PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 274 VIETNAM ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 275 VIETNAM ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 276 VIETNAM NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 277 VIETNAM CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 278 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 279 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 280 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 281 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 282 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 283 REST OF ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

Lista de Figura

FIGURE 1 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: ASIA-PACIFIC VS. REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 11 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028

FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE LYOPHILIZED INJECTABLE DRUGS MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET

FIGURE 16 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020

FIGURE 17 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)

FIGURE 18 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)

FIGURE 19 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE

FIGURE 20 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020

FIGURE 21 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)

FIGURE 22 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)

FIGURE 23 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE

FIGURE 24 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020

FIGURE 25 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)

FIGURE 26 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)

FIGURE 27 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE

FIGURE 28 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020

FIGURE 29 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 30 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 31 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 32 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 33 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

FIGURE 34 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 35 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020

FIGURE 37 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 38 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 39 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 41 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 42 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 43 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)

FIGURE 45 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)

FIGURE 46 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 47 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 48 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING (2021-2028)

FIGURE 49 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.